One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market
The biotech company is awaiting approval on a second drug to drive up revenue as it firms its foothold in a competitive landscape Key Takeaways: Boan Biotechnology sells only one…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
- InSilico seeks IPO boost to get AI drugs over the line
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
Discover hidden China stock gems in our weekly newsletter